Book running lead managers (BRLM) to GreenSignal Bio Pharma has informed the exchange that the issue closure date has been extended up to November 17. Post issue modification date has been revised to November 18.
Till Friday the IPO, which opened for subscription on November 9, got subscribed just 82 per cent.
The offer was earlier scheduled to close on Friday.
The company has entered the capital market with its IPO of 1,45,79,560 shares of face value of Rs 10 each through an offer for sale. It has fixed the price band at Rs 76-80.
The firm is into manufacturing of BCG vaccine given for protection against tuberculosis, mainly severe forms of child tuberculosis.
GreenSignal Bio Pharma is the 25th company to hit the market with its IPO this year.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%